NZ502445A - Control of acidic gut syndrome - Google Patents

Control of acidic gut syndrome

Info

Publication number
NZ502445A
NZ502445A NZ502445A NZ50244598A NZ502445A NZ 502445 A NZ502445 A NZ 502445A NZ 502445 A NZ502445 A NZ 502445A NZ 50244598 A NZ50244598 A NZ 50244598A NZ 502445 A NZ502445 A NZ 502445A
Authority
NZ
New Zealand
Prior art keywords
control
gut syndrome
acidic gut
acidic
animal
Prior art date
Application number
NZ502445A
Inventor
James Baber Rowe
Original Assignee
Univ New England
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New England filed Critical Univ New England
Publication of NZ502445A publication Critical patent/NZ502445A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Use of an active agent capable of preventing or controlling acid and endotoxin accumulation in the gastrointestinal tract of a human or animal, for the preparation of a medicament for the treatment or prophylaxis of acidic gut syndrome resulting from the inflammation of the gut wall of the human or animal, the inflammation resulting from the presence of acid acting on the gut wall.
NZ502445A 1997-06-27 1998-06-26 Control of acidic gut syndrome NZ502445A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO7582A AUPO758297A0 (en) 1997-06-27 1997-06-27 Control of acidic gut syndrome
PCT/AU1998/000495 WO1999000136A1 (en) 1997-06-27 1998-06-26 Control of acidic gut syndrome

Publications (1)

Publication Number Publication Date
NZ502445A true NZ502445A (en) 2003-03-28

Family

ID=3801872

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ502445A NZ502445A (en) 1997-06-27 1998-06-26 Control of acidic gut syndrome

Country Status (8)

Country Link
US (2) US6303572B1 (en)
EP (1) EP1017402A4 (en)
JP (1) JP2002511865A (en)
AU (1) AUPO758297A0 (en)
BR (1) BR9810944A (en)
CA (1) CA2294904A1 (en)
NZ (1) NZ502445A (en)
WO (1) WO1999000136A1 (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO758297A0 (en) * 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
AUPQ137699A0 (en) * 1999-07-02 1999-07-22 University Of New England, The Control of acidosis
CZ302015B6 (en) 1999-10-08 2010-09-08 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6861071B2 (en) * 2000-08-08 2005-03-01 Daiichi Pharmaceutical Co., Ltd. Highly absorptive solid preparation
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
ATE420640T1 (en) * 2001-04-06 2009-01-15 Affinium Pharm Inc FAB I INHIBITORS
WO2002080947A1 (en) * 2001-04-06 2002-10-17 Kyodoken Institute For Animal Science Research & Development Compositions containing bacterium capable of converting lactic acid into butyric acid and method of preventing/treating hyperlactic acidemia in digestive tract and colon cancer by using the same
ATE469639T1 (en) * 2001-08-08 2010-06-15 Dominguez Maria Antonia Garcia-Olmedo INJECTABLE FOAM AND NEW PHARMACEUTICAL APPLICATIONS THEREOF
AU2003260668A1 (en) * 2002-04-01 2003-10-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
GB0209262D0 (en) 2002-04-23 2002-06-05 Biochemie Gmbh Organic compounds
US7740838B2 (en) * 2002-12-05 2010-06-22 Danisco A/S Bacterial composition and its use
DK1575951T3 (en) * 2002-12-06 2014-09-15 Debiopharm Int Sa HETEROCYCLIC COMPOUNDS, METHODS OF PRODUCING THEREOF AND THEIR USE IN THERAPY
US7252836B2 (en) 2003-01-13 2007-08-07 Penwest, Ltd. Food and feed compositions including resistant starch
US8519008B2 (en) 2003-01-22 2013-08-27 Purina Animal Nutrition Llc Method and composition for improving the health of young monogastric mammals
EP1608377B1 (en) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
AU2004258944B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2533178C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1653925A1 (en) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
JP2007502294A (en) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション Antibiotic preparations, their use and preparation
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
NO319624B1 (en) 2003-09-15 2005-09-05 Trouw Internat Bv Fish feed for salmonids in fresh water and use of such feed.
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1679962B1 (en) * 2003-10-20 2021-01-13 Framework Therapeutics, L.L.C. Zeolite molecular sieves for the removal of toxins
DE10350409A1 (en) * 2003-10-28 2005-05-25 Bayer Healthcare Ag Method employing quinolones and related substances for treatment and prophylaxis of genetic diseases causing local mutations and comparable defects in higher organisms, including human beings
US20050220846A1 (en) * 2004-04-05 2005-10-06 Puntenney Steven B Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
SI1828167T1 (en) * 2004-06-04 2014-12-31 Debiopharm International Sa Forum "Apres-Demain" Acrylamide derivatives as antibiotic agents
EP1771158A4 (en) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp Tablet for pulsed delivery
US20060018843A1 (en) * 2004-07-24 2006-01-26 Fine Kenneth D Halitosis, gingivitis, and periodontitis treatment and preventative composition
US7611732B2 (en) * 2004-07-26 2009-11-03 Michael Bentley Nutritional supplement for osteoarthritis
CA2614769A1 (en) * 2005-03-10 2006-09-21 Verenium Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
US8426184B2 (en) 2005-03-15 2013-04-23 Bp Corporation North America Cellulases, nucleic acids encoding them and methods for making and using them
WO2007067416A2 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
WO2007068055A1 (en) * 2005-12-15 2007-06-21 Hancroft Pty Ltd A method for preventing reduced feed intake in animals and treatment of disease conditions
EP2420570B1 (en) 2006-02-10 2013-12-04 Verenium Corporation Arabinofuranosidase enzymes, nucleic acids encoding them and methods for making and using them
JP5441417B2 (en) 2006-03-07 2014-03-12 カーギル・インコーポレイテッド Aldose, nucleic acid encoding it, and methods of generating and using it
ES2383767T3 (en) 2006-03-07 2012-06-26 Verenium Corporation Aldolases, nucleic acids that encode them and methods to produce and use them
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US20110027346A1 (en) * 2006-06-02 2011-02-03 Verenium Corporation Lyase Enzymes, Nucleic Acids Encoding Them and Methods for Making and Using Them
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
BRPI0719449A2 (en) 2006-12-21 2017-06-20 Syngenta Participations Ag isolated, synthetic or recombinant nucleic acid molecule, isolated polypeptide, plant or part of plant, cloning vehicle comprising a nucleic acid, expression cassette comprising a nucleic acid molecule and method for hydrolyzing a polysaccharide, oligosaccharide or starch
AR065544A1 (en) 2007-01-30 2009-06-17 Verenium Corp ENZYMES FOR THE TREATMENT OF NUCLEIC ACID LIGNOCELLULOSICS THAT CODE AND METHODS TO PREPARE AND USE THEM
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
US8481084B2 (en) * 2007-05-23 2013-07-09 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
US20120058157A1 (en) * 2007-05-23 2012-03-08 Amcol International Corporation Methods of Treating Cardiovascular Disorders Associated with Atherosclerosis
JP2014502144A (en) 2010-10-06 2014-01-30 ビーピー・コーポレーション・ノース・アメリカ・インコーポレーテッド Variant CBHI polypeptide
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
DE102012207471A1 (en) * 2012-05-04 2013-11-07 Fim Biotech Gmbh Mineral compound and its modifications for use in inflammatory bowel disease
IN2012DE01792A (en) 2012-06-11 2015-10-16 Council Scient Ind Res
MX356695B (en) 2012-06-19 2018-06-11 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)m ethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylam ide.
ITBS20120137A1 (en) * 2012-09-06 2014-03-07 Ecobase Gmbh USE OF A MICRONIZED ZEOLITE
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
LT3003327T (en) 2013-06-05 2017-12-27 Tricida Inc. Proton-binding polymers for oral administration
KR20160025524A (en) * 2013-06-26 2016-03-08 타슬리 파마슈티컬 그룹 컴퍼니 리미티드 Use of chinese medicine preparation in preparing drug for preventing and/or treating crohn's disease
US10383921B2 (en) 2013-08-13 2019-08-20 President And Fellows Of Harvard College Leveraging oxidative stress pathways in lactic acid bacteria to promote gut homeostasis
EP2870967A1 (en) * 2013-11-08 2015-05-13 Glock Health GmbH Klinoptiloloith for use in treating inflammatory bowel diseases
WO2015123456A1 (en) 2014-02-12 2015-08-20 OmniGen Research, L.L.C. Composition and method for promoting reduction of heat stress in animals
ES2857177T3 (en) 2014-12-10 2021-09-28 Tricida Inc Proton-binding polymers for oral administration
EP3065748B1 (en) 2014-12-23 2017-11-22 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and its use in reducing inflammation
HUE037476T2 (en) 2014-12-23 2018-08-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3240554T3 (en) 2015-06-15 2020-02-28 4D Pharma Research Limited Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
EP3307288B1 (en) 2015-06-15 2019-07-24 4D Pharma Research Limited Compositions comprising bacterial strains
RS63089B1 (en) 2015-06-15 2022-04-29 4D Pharma Res Ltd Compositions comprising bacterial strains
US20170095508A1 (en) * 2015-09-15 2017-04-06 Nutriquest, Llc Antimicrobial clay compositions and methods of using
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41013B1 (en) 2015-11-20 2018-07-31 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
KR20180114177A (en) 2016-02-26 2018-10-17 데비오팜 인터네셔날 에스 에이 Treatment of Diabetic Foot Infection
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
PT3313423T (en) 2016-03-04 2019-07-10 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
US20190209607A1 (en) 2016-05-06 2019-07-11 Tricida, Inc. Compositions for treating acid-base disorders
TWI802545B (en) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
PT3630136T (en) 2017-05-22 2021-06-11 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41708A (en) 2017-05-24 2020-04-08 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS
MD3638271T2 (en) 2017-06-14 2021-03-31 4D Pharma Res Ltd Compositions comprising bacterial strains
HRP20220747T1 (en) 2017-06-14 2022-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
WO2019023320A1 (en) * 2017-07-25 2019-01-31 Arizona Board Of Regents On Behalf Of Arizona State University Rapid antibiotic susceptibility testing by tracking sub-micron scale motion of single bacterial cells
US11266684B2 (en) 2017-11-03 2022-03-08 Tricida, Inc. Compositions for and method of treating acid-base disorders
EP3975746A4 (en) 2019-05-31 2023-05-31 Nutriquest, LLC Therapeutic clay compositions and methods of using
CN113769064A (en) * 2021-09-28 2021-12-10 上海交通大学医学院附属第九人民医院 Application of thiostrepton in preparation of medicine for treating periodontitis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336811C (en) * 1988-03-30 1995-08-29 James Baber Rowe Treatment of equine livestock with antibiotics
AU698600B2 (en) * 1994-12-29 1998-11-05 James Baber Rowe Prevention of adverse behaviour, diarrhoea, skin disorders and infections of the hindgut associated with acidic conditions in humans and animals
AUPO758297A0 (en) * 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome

Also Published As

Publication number Publication date
EP1017402A4 (en) 2001-05-30
CA2294904A1 (en) 1999-01-07
BR9810944A (en) 2000-09-26
WO1999000136A1 (en) 1999-01-07
EP1017402A1 (en) 2000-07-12
JP2002511865A (en) 2002-04-16
US6303572B1 (en) 2001-10-16
US6468964B1 (en) 2002-10-22
AUPO758297A0 (en) 1997-07-24

Similar Documents

Publication Publication Date Title
NZ502445A (en) Control of acidic gut syndrome
AU6158001A (en) Drug/drug delivery systems for the prevention and treatment of vascular disease
EE9700192A (en) Oral pharmaceutical dosage form comprising a proton pump inhibitor and an antacid or alginate
ZA991408B (en) Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent.
HK1037320A1 (en) Use of anti.microtubule agents for treating inflammatory respiratory diseases of the respiratory tract
ZA995839B (en) Orally administered controlled drug delivery system providing temporal and spatial control.
PT1441705E (en) Solid, stabilized, prompt- and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs
AU3699397A (en) Polynucleotide vaccine formula for treating dog diseases, particularly respiratory and digestive diseases
EP1600168A3 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
MX9604354A (en) New oral pharmaceutical dosage form.
AU6411199A (en) Angiogenically effective unit dose of fgf and method of administering
NO994165L (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
NO994431L (en) New wording
PT1206257E (en) USE OF AMINO ACIDS FOR THE MANUFACTURE OF MEDICINES INTENDED FOR THE TREATMENT OF INSULIN RESISTANCE
ZA968990B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.
IT1290781B1 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
AU3593599A (en) Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof
WO2001028535A3 (en) Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
HK1061209A1 (en) Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
DK0951290T3 (en) Absorbable composition containing propionic acid bacteria capable of delivering nitric oxide into the digestive tract of a human or animal
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
WO2002090552A3 (en) Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
WO1996036324A3 (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
IT240104Y1 (en) DEVICE FOR THE TREATMENT OF THE HUMAN BODY.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: JAMES BABER ROWE, AU

Free format text: OLD OWNER(S): THE UNIVERSITY OF NEW ENGLAND